Malaria antigen (N/A)

Malaria antigens are a broad category of proteins and molecules expressed by Plasmodium parasites, including P. falciparum and P. vivax, at various stages of their life cycle (WHO, 2023). These antigens are critical for the parasite's survival, motility, and ability to invade host cells, making them primary targets for both diagnostic and therapeutic development. The most prominent therapeutic target is the Circumsporozoite protein (CSP), which is the basis for the WHO-approved RTS,S/AS01 and R21/Matrix-M vaccines designed to prevent liver-stage infection (Nature, 2022). Other antigens, such as Histidine-rich protein 2 (HRP2), are essential for rapid diagnostic tests, as they are secreted into the host's blood during the erythrocytic stage (CDC, 2024). Additional targets like Merozoite Surface Protein 1 (MSP1) and Apical Membrane Antigen 1 (AMA1) are involved in red blood cell invasion and are being explored for blood-stage vaccines (PubMed, 2021). Therapeutic strategies aim to induce neutralizing antibodies or T-cell responses to interrupt the parasite's life cycle. However, the high degree of genetic polymorphism and the parasite's capacity for antigenic variation remain significant obstacles to achieving universal and long-lasting protection (Science, 2023).

Other names

Plasmodium antigenMalarial proteinParasite-derived antigenPlasmodium falciparum antigen

Vaccines and monoclonal antibodies target specific malaria antigens to elicit an immune response that neutralizes the parasite's ability to invade host cells, such as hepatocytes or erythrocytes; diagnostic assays use them as capture targets to detect active infection.